Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00746499 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.
A Phase 1 study of Pharmacokinetics, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT00746499: Completed Phase 1 study of Pharmacokinetics, sponsored by University of North Carolina, Chapel Hill.
NCT00746499 is a Phase 1 study of Pharmacokinetics that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 7 participants, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00746499, a Phase 1 study of Pharmacokinetics, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
Healthy subjects will take study drug by mouth twice a day for 7 consecutive days, blood and cervicovaginal samples will be taken most mornings around the AM dose. Two visits, \~14 hrs in length will be required on Day 1 and 7. The purpose of this study is to measure how much raltegravir is found in the genital tract after taking it orally.
Conditions Studied
Interventions
- DRUG Raltegravir
Study Locations (1)
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-09 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
What the finished NCT00746499 record still lists
NCT00746499 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Pharmacokinetics appearing as the primary indexed condition, and to 1 intervention - of which Raltegravir is the first listed.
NCT00746499 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00746499 about?
NCT00746499 is a clinical study titled "Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.". Healthy subjects will take study drug by mouth twice a day for 7 consecutive days, blood and cervicovaginal samples will be taken most mornings around the AM dose. Two visits, \~14 hrs in length will be required on Day 1 and 7. The purpose of this study is to measure how much raltegravir is found in...
What is the current status of trial NCT00746499?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2008-09. Estimated completion is 2008-11.
What conditions does trial NCT00746499 study?
This clinical trial studies the following conditions: Pharmacokinetics.
What interventions are being tested in trial NCT00746499?
The interventions under investigation include: Raltegravir (DRUG).
Who is sponsoring clinical trial NCT00746499?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00746499 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacokinetics
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00746499's enrollment target sits among peer trials
7 36th of 37 higher than 2 of 37 other Pharmacokinetics trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pharmacokinetics trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
RECRUITING · Phase 1
-
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
RECRUITING · Phase 1
-
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
RECRUITING · Phase 1
-
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia